Publications (141) Jesús Pérez Sánchez-Toledo publications

filter_list

2025

  1. A network approach exploring the effects of cognitive remediation on cognition, symptoms, and functioning in early psychosis

    Psychological Medicine, Vol. 55

  2. Author Correction: The impact of the initial COVID-19 outbreak on young adults’ mental health: a longitudinal study of risk and resilience factors (Scientific Reports, (2022), 12, 1, (16659), 10.1038/s41598-022-21053-2)

    Scientific Reports

  3. Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program

    Schizophrenia Bulletin Open, Vol. 6, Núm. 1

  4. Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  5. Effect of Cognitive Training on Cancer-Related Cognitive Impairment in Patients With Breast Cancer: A Systematic Review and Meta-Analysis

    Psycho-Oncology, Vol. 34, Núm. 8

  6. Effect of Physical Exercise on Telomere Length: Umbrella Review and Meta-Analysis

    JMIR AGING, Vol. 8

  7. Improving Collaboration Between Primary and Secondary Mental Healthcare via Boundary Spanning: Evaluation of a New Joined-Up Community Mental Healthcare Model in England

    International Journal of Health Planning and Management, Vol. 40, Núm. 5, pp. 1140-1150

  8. Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis

    Journal of Psychiatric Research, Vol. 186, pp. 33-49

  9. Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program

    Schizophrenia Bulletin Open, Vol. 6, Núm. 1

  10. Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  11. Suicidality among people with mild cognitive impairment: a sustematic review

    BMC Psychiatry, Vol. 25, Núm. 1

  12. The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

    Schizophrenia, Vol. 11, Núm. 1

  13. The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

    Schizophrenia, Vol. 11, Núm. 1

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Body Awareness as a Protective Factor against Suicidal Orientations in College Students

    Behavioral Sciences, Vol. 14, Núm. 5

  3. Cognitive remediation therapy to enhance cognition and improve recovery in early psychosis: the ECLIPSE research programme including an RCT

    Programme Grants for Applied Research, Vol. 12, Núm. 4

  4. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  5. Effect of strength-based physical exercise on telomere length as a marker of premature ageing in patients with schizophrenia: study protocol for a pilot randomised controlled trial

    BJPsych Open, Vol. 10, Núm. 5

  6. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

    World Psychiatry

  7. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

    Psychological Medicine, Vol. 54, Núm. 5, pp. 993-1003